Responding to the Pandemic of Falsified Medicines
| Autor: | M. Julia Culzoni, Megan Kendall, Paul N. Newton, James E. Herrington, Amir Attaran, Joel G. Breman, Gaurvika M. L. Nayyar, Facundo M. Fernández, John P. Clark |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Quality Control
CIENCIAS MÉDICAS Y DE LA SALUD Internationality Policy Perspectives media_common.quotation_subject 030231 tropical medicine Ciencias de la Salud Poison control Legislation Global Health PANDEMIC POLICY PERSPECTIVES LABORATORY AND FIELD INNOVATIONS purl.org/becyt/ford/3.3 [https] 03 medical and health sciences 0302 clinical medicine Virology Environmental health FALSIFIED MEDICINES Medicine Quality (business) 030212 general & internal medicine Health policy media_common Sustainable development Salud Ocupacional business.industry Health Policy 1. No poverty Public relations Millennium Development Goals Legislation Drug 3. Good health Counterfeit Infectious Diseases Counterfeit Drugs Accountability purl.org/becyt/ford/3 [https] Parasitology business |
| Zdroj: | CONICET Digital (CONICET) Consejo Nacional de Investigaciones Científicas y Técnicas instacron:CONICET The American Journal of Tropical Medicine and Hygiene |
| ISSN: | 1476-1645 0002-9637 |
| Popis: | Over the past decade, the number of countries reporting falsified (fake, spurious/falsely labeled/counterfeit) medicines and the types and quantities of fraudulent drugs being distributed have increased greatly. The obstacles in combating falsified pharmaceuticals include 1) lack of consensus on definitions, 2) paucity of reliable and scalable technology to detect fakes before they reach patients, 3) poor global and national leadership and accountability systems for combating this scourge, and 4) deficient manufacturing and regulatory challenges, especially in China and India where fake products often originate. The major needs to improve the quality of the world?s medicines fall into three main areas: 1) research to develop and compare accurate and affordable tools to identify high-quality drugs at all levels of distribution; 2) an international convention and national legislation to facilitate production and utilization of high-quality drugs and protect all countries from the criminal and the negligent who make, distribute, and sell life-threatening products; and 3) a highly qualified, well-supported international science and public health organization that will establish standards, drug-quality surveillance, and training programs like the U.S. Food and Drug Administration. Such leadership would give authoritative guidance for countries in cooperation with national medical regulatory agencies, pharmaceutical companies, and international agencies, all of which have an urgent interest and investment in ensuring that patients throughout the world have access to good quality medicines. The organization would also advocate strongly for including targets for achieving good quality medicines in the United Nations Millennium Development Goals and Sustainable Development Goals. Fil: Nayyar, Gaurvika M. L.. University Johns Hopkins; Estados Unidos Fil: Attaran, Amir. University of Otawa; Canadá Fil: Clark, John P.. Pfizer Pharmaceuticals; Estados Unidos Fil: Culzoni, Maria Julia. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe; Argentina Fil: Fernandez, Facundo M.. University of North Carolina; Estados Unidos Fil: Herrington, James E.. University of Otawa; Canadá Fil: Kendall, Megan. Lao-Oxford-Mahosot Hospital; Reino Unido Fil: Newton, Paul N.. University of Oxford; Reino Unido Fil: Breman, Joel G.. National Institutes of Health; Estados Unidos |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|